Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

ClinicalTrials.gov ID: NCT02110706

Public ClinicalTrials.gov record NCT02110706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Study identification

NCT ID
NCT02110706
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yale University
Other
Enrollment
52 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
21 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Jun 30, 2017
Completion
Apr 30, 2018
Last update posted
Mar 5, 2020

2014 – 2018

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
25
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
University of California - Davis Davis California 95616
University of California - Los Angeles Los Angeles California 90095
University of Colorado - Denver Denver Colorado 80217
Yale School of Medicine, Department of Neurology New Haven Connecticut 06510
University of Miami School of Medicine Miami Florida 33136
Emory University Atlanta Georgia 30322
Northwestern University Evanston Illinois 60208
University of Kansas Medical Center Kansas City Kansas 66160
Brigham & Women's Hospital Boston Massachusetts 02115
Washington University St Louis Missouri 63130
SUNY Downstate Medical Center Brooklyn New York 11203
SUNY Buffalo Buffalo New York 14260
Columbia University Medical Center New York New York 10032
Weill Cornell Medical Center New York New York 10065
University of Rochester Rochester New York 14627
SUNY Stony Brook Stony Brook New York 11790
Montefiore Medical Center The Bronx New York 10461
University of Cincinnati Cincinnati Ohio 45220
Ohio State University Columbus Ohio 43210
Oregon Health and Science University Portland Oregon 97239
University of Pittsburgh Pittsburgh Pennsylvania 15260
University of Texas Southwestern Medical Center Dallas Texas 75235
University of Utah Salt Lake City Utah 84112
University of Virginia Charlottesville Virginia 22904
Swedish Medical Center Seattle Washington 98107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02110706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2020 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02110706 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →